Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Phase 1 assessment of novel transposon BAFF CAR-T cells (LMY-920) for non-Hodgkin lymphoma (NHL) and multiple myeloma (MM)

View Full Paper
Ask AI
Bookmark
Share

Authors

PCPaolo CaimiLMLeland MethenyMSMatthew Spear

Discussion

Loading...

Member takes

Overview

Open-label trial evaluates BAFF CAR-T cell effect on immune dysregulation in non-Hodgkin lymphoma, suggesting improved treatment options.

Key Points

  • To assess the efficacy and safety of BAFF CAR-T cells (LMY-920) in patients with non-Hodgkin lymphoma and multiple myeloma.
  • Phase 1 open-label dose escalation trials in NHL and MM
  • Inclusion of patients with disease progression after prior therapies
  • Manufacturing of LMY-920 CAR-T cells using the BAFF-CAR transposon construct
  • Administering lymphodepleting chemotherapy before LMY-920 infusion
  • Response assessed using Lugano and IMWG criteria.
  • Response rates evaluated according to established criteria
  • Potential reduction in T cell exhaustion with BAFF targeting
  • Safe administration of escalating doses of LMY-920

Cite This Study

Caimi et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d5aehttps://doi.org/10.1182/blood-2025-1954
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Novel transposon BAFF CAR-T cells (LMY-920) for non-Hodgkin lymphoma (NHL).2026
  2. 2PMB-CT01 (BAFFR-CAR T cell) therapy to examine preliminary safety and clinical responses in patients with B-cell malignancies who are ineligible for or failed CD19-directed therapy, including CD19-negative disease.2024 · 4 citations
  3. 3BAFFR-CAR T cells (PMB-CT01) demonstrate durable responses and manageable toxicities in relapsed/refractory B-cell lymphomas with prior CD19-directed therapy failure or CD19-negative disease2025
  4. 4A first-in-human Phase 1 trial of LY4152199, a B-cell activation factor receptor (BAFF-R) T-cell engager bispecific antibody, in patients with previously treated B-cell malignancies (BAF_FRontier-1 Trial in Progress)2025
  5. 5Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma.2017 · 67 citations